Zyversa Therapeutics Inc.
13F holders, Q1 2024 (March 31)8holders
$0.74avg. 13F price*
At the end of Q1 2024, 8 institutions reported holding Zyversa Therapeutics Inc. in their 13F filings. The largest holders were Two Sigma Securities, LLC ($23K), Cubist Systematic Strategies, LLC ($22K) and UBS Group AG ($15K).
- Company
- Zyversa Therapeutics Inc.
- CUSIP
- 98987D201
- Latest filing quarter
- Q1 2024
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $40K |
| Exits | 2 | $158K |
Ownership 8 holders
| Two Sigma Securities, LLC | 0.00% | Add +67.1% | 31,205 | $23K |
| Cubist Systematic Strategies, LLC | 0.00% | New | 29,366 | $22K |
| UBS Group AG | 0.00% | Add +508.1% | 19,909 | $15K |
| Jane Street Group, LLC | 0.00% | New | 12,120 | $9K |
| HRT Financial LP | 0.00% | New | 13,176 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +114.6% | 8,542 | $6K |
| Wells Fargo & Company | 0.00% | Add +10.0% | 11 | $9 |
| JPMorgan Chase & Co. | 0.00% | New | 1 | $1 |
"% of holder's portfolio" is ZYVERSA THERAPEUTICS INC's weight in each manager's 13F, not the share of Zyversa Therapeutics Inc. the manager owns.